Baidu
map

JCEM:HDL颗粒亚型及其与2型糖尿病之间的关联

2021-02-13 MedSci原创 MedSci原创

较大HDL颗粒且较低H2P含量与较低T2D风险相关,而较高H2P水平与较高的T2D风险相关。此外,在非肥胖受试者中,较大的HDL颗粒和H6P与T2D风险呈负相关。

高密度脂蛋白(HDL)可以预防2型糖尿病(T2D)的发展,但是HDL颗粒的大小和功能各不相同,这可能导致其与T2D发生发展之间的关联存在差异。一种新开发的核磁共振(NMR)衍生算法可以获得七种HDL亚型的浓度。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究旨在调查普通人群中HDL颗粒亚型与T2D事件之间的相关性。

在肾脏和血管末期疾病预防试验(PREVEND)4828名基线无T2D的受试者中。研究人员通过NMR(Vantera NMR平台的LP4算法)测量了从H1P到H7P颗粒大小逐渐增加的HDL亚型。

265名受试者发生了T2D(中位随访时间为7.3年)。在Cox回归模型中,调整相关协变量后,HDL大小和H4P[每增加1个SD的HR为0.83(95%CI为0.69-0.99)和0.85(95%CI为0.75-0.95)]与T2D发生呈负相关。H2P水平与T2D事件呈正相关(HR为1.15(95%CI为1.01-1.32)。在次要分析中,BMI调整了较大HDL颗粒和H6P与T2D发生风险之间的关联,尤其是在BMI<30 kg/m2的受试者中。

由此可见,较大HDL颗粒且较低H2P含量与较低T2D风险相关,而较高H2P水平与较高的T2D风险相关。此外,在非肥胖受试者中,较大的HDL颗粒和H6P与T2D风险呈负相关

原始出处:

Sara Sokooti.et al.HDL particle subspecies and their association with incident type 2 diabetes: the PREVEND study.JCEM.2021.https://doi.org/10.1210/clinem/dgab075

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063405, encodeId=211e206340577, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Jun 04 08:13:00 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778023, encodeId=22b81e7802305, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 02 02:13:00 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316453, encodeId=8f041316453f4, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Feb 15 04:13:00 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043508, encodeId=691210435080b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 16:13:00 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-06-04 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063405, encodeId=211e206340577, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Jun 04 08:13:00 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778023, encodeId=22b81e7802305, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 02 02:13:00 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316453, encodeId=8f041316453f4, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Feb 15 04:13:00 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043508, encodeId=691210435080b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 16:13:00 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-03-02 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063405, encodeId=211e206340577, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Jun 04 08:13:00 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778023, encodeId=22b81e7802305, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 02 02:13:00 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316453, encodeId=8f041316453f4, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Feb 15 04:13:00 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043508, encodeId=691210435080b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 16:13:00 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-15 ZGMFX24A
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063405, encodeId=211e206340577, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Jun 04 08:13:00 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778023, encodeId=22b81e7802305, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Mar 02 02:13:00 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316453, encodeId=8f041316453f4, content=<a href='/topic/show?id=73f386080a' target=_blank style='color:#2F92EE;'>#HDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8608, encryptionId=73f386080a, topicName=HDL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Mon Feb 15 04:13:00 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043508, encodeId=691210435080b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 13 16:13:00 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-13 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

JCEM:多因素干预对2型糖尿病患者骨折的影响

在不增加2型糖尿病患者骨折风险的情况下,可以实施强化治疗的多因素干预。有吸烟史的男性发生骨折的风险升高,而FRAX评分可预测骨折风险,女性服用吡格列酮可独立增加骨折风险。

J Periodontol:Omega-3 PUFA和阿司匹林可作为牙周炎和2型糖尿病患者牙周清创术的辅助治疗手段

有学者提出将补充ω-3多不饱和脂肪酸(ω-3 PUFA)和低剂量阿司匹林(ASA)作为控制慢性炎症性疾病的宿主调节方案,尚缺乏高质量的临床研究加以证实。近期,发表于J Peri

Circulation:恩格列净可逆转合并2型糖尿病的HFrEF患者的心室重构!

钠葡萄糖共转运蛋白2抑制剂可降低射血分数降低的心力衰竭(HFrEF)患者心衰住院和心血管死亡的风险。

JAMA Netw Open:坚持地中海饮食,2型糖尿病患病风险降低30%

近年来,地中海饮食作为全球公认的健康膳食结构之一,备受关注。来越多的证据显示,坚持地中海饮食可以降低糖尿病、代谢综合征及阿尔茨海默病的发病风险。

EClinicalMedicine:合并2型糖尿病和或慢性肾病的心衰患者近20多年的预后变化趋势

心力衰竭(HF)与2型糖尿病(T2D)和慢性肾脏病(CKD)一起是二十世纪的三大主要流行病。

JCEM:二甲双胍与2型糖尿病患者COVID-19易感性之间的关系

二甲双胍与COVID-19风险或COVID-19相关死亡无关。由此可见,继续使用二甲双胍改善糖尿病患者的血糖控制是安全的。

Baidu
map
Baidu
map
Baidu
map